West Pharmaceutical Services (WST) is down 5.3% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver appears to be profit-taking after a sharp earnings-driven rally the prior session rather than a fresh company-specific setback. West had just posted a strong second quarter, beat expectations, and raised guidance, so today’s decline may reflect investors locking in gains after the stock pushed to a new high.
Details:
Sources:
SEC, West Pharmaceutical Services, Investing.com, OpenAI Finance
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$WST Insider Trading Activity
$WST insiders have traded $WST stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $WST stock by insiders over the last 6 months:
- ANNETTE F FAVORITE (Sr. VP & Chief HR Officer) sold 2,817 shares for an estimated $859,753
- CHAD WINTERS (VP, Chief Accounting Officer) sold 896 shares for an estimated $269,399
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$WST Hedge Fund Activity
We have seen 316 institutional investors add shares of $WST stock to their portfolio, and 373 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 1,140,094 shares (+1039.7%) to their portfolio in Q1 2026, for an estimated $285,753,160
- FRANKLIN RESOURCES INC removed 876,596 shares (-98.7%) from their portfolio in Q1 2026, for an estimated $219,710,021
- GENERATION INVESTMENT MANAGEMENT LLP added 682,107 shares (+43.7%) to their portfolio in Q1 2026, for an estimated $170,963,298
- CAPITAL RESEARCH GLOBAL INVESTORS added 604,011 shares (+inf%) to their portfolio in Q1 2026, for an estimated $151,389,317
- BROWN ADVISORY INC removed 602,729 shares (-31.0%) from their portfolio in Q1 2026, for an estimated $151,067,996
- STEADFAST CAPITAL MANAGEMENT LP removed 429,907 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $107,751,890
- AMUNDI added 296,639 shares (+85.4%) to their portfolio in Q1 2026, for an estimated $74,349,598
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$WST Analyst Ratings
Wall Street analysts have issued reports on $WST in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wolfe Research issued a "Outperform" rating on 06/02/2026
To track analyst ratings and price targets for $WST, check out Quiver Quantitative's $WST forecast page.
$WST Price Targets
Multiple analysts have issued price targets for $WST recently. We have seen 5 analysts offer price targets for $WST in the last 6 months, with a median target of $390.0.
Here are some recent targets:
- Kallum Titchmarsh from Morgan Stanley set a target price of $365.0 on 07/09/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $410.0 on 07/06/2026
- Paul Knight from Keybanc set a target price of $390.0 on 07/02/2026
- Luke Sergott from Barclays set a target price of $400.0 on 06/09/2026
- Steven Etoch from Stephens & Co. set a target price of $360.0 on 06/02/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
